Literature DB >> 32007192

Availability of anticancer biosimilars in 40 countries.

Hui-Yao Huang1, Da-Wei Wu1, Fei Ma2, Zhi-Lei Liu3, Ju-Fang Shi4, Xia Chen5, Shu-Hang Wang1, Hong Fang1, Ying Bai1, Yue Yu1, Yuan Fang1, Chao Sun1, Qi Fan1, Ying Wu6, Rui-Hua Fan7, Cai-Yun Zhou8, Bao-Xia He9, Min Dai4, Ning Li10, Bing-He Xu1, Yan Sun1, Jie He11.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32007192     DOI： 10.1016/S1470-2045(19)30860-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Xian Xiao; Guixing Zhang; Binxu Sun; Chaoran Wang; Xiaoqun Wang; Fanming Kong; Yingjie Jia
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

2.  Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial.

Authors:  Tianqing Chu; Jun Lu; Minghong Bi; Helong Zhang; Wu Zhuang; Yan Yu; Jianhua Shi; Zhendong Chen; Xiaochun Zhang; Qisen Guo; Quan Liu; Huijuan Wu; Jian Fang; Yi Hu; Xiuwen Wang; Cuicui Han; Kai Li; Baohui Han
Journal:  Cancer Biol Med       Date:  2021-03-12       Impact factor: 4.248

3.  Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.

Authors:  Jun Lu; Tianqing Chu; Hongyu Liu; Minjuan Hu; Yuqing Lou; Yanwei Zhang; Zhiqiang Gao; Wei Zhang; Xueyan Zhang; Huimin Wang; Hua Zhong; Baohui Han
Journal:  Chin J Cancer Res       Date:  2022-02-28       Impact factor: 5.087
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.